Dabigatran-d7

Dabigatran-d7 (BIBR 953-d7; BIBR 953ZW-d7) is the deuterium labeled Dabigatran (HY-10163) . Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM) . Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) [1][2].

Product Specifications

CAS Number

[2512224-24-5]

Product Name Alternative

BIBR 953-d7; BIBR 953ZW-d7

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Thrombin

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cardiovascular Disease

Smiles

OC(CCN(C1=C([2H])C([2H])=C([2H])C([2H])=N1)C(C2=CC=C(C(N=C3CNC4=CC=C(C=C4)C(N)=N)=C2)N3C([2H])([2H])[2H])=O)=O

Molecular Formula

C25H18D7N7O3

Molecular Weight

478.55

References & Citations

[1]Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[2]Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45 (9) :1757-66.|[3]Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98 (2) :333-8.